Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 5/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.31 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034552 | 0.91 | PTPN1 (0.33) | KDM1AKDM1BKCNH2USP28NPC1 | |
| SCHEMBL24697715 | 0.88 | KDM1A (0.36) | KDM1AKDM1BKCNH2CYP1A2CYP2D6 | |
| SCHEMBL31614825 | 0.86 | NPC1 (0.31) | NPC1RAB9APTGDR2 | |
| SCHEMBL1315369 | 0.86 | PTPN1 (0.33) | USP28NPC1RAB9APTGDR2 | |
| SCHEMBL523311 | 0.84 | GRIA1 (0.35) | USP28MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL30574768 | 0.84 | PTPN1 (0.37) | KDM1AKDM1BKCNH2 | |
| SCHEMBL1773032 | 0.84 | PTPN1 (0.37) | KDM1AKDM1BKCNH2 | |
| SCHEMBL707949 | 0.83 | KDM1A (0.32) | KDM1AKDM1BKCNH2USP28 | |
| SCHEMBL29387214 | 0.83 | KDM1A (0.32) | KDM1AKDM1BKCNH2USP28 | |
| SCHEMBL2554312 | 0.80 | KDM1A (0.44) | KDM1AKDM1BKCNH2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741389-A1 | KAT6 INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4626860-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | ReWind Therapeutics NV (BE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4561565-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | Insmed Incorporated (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025007873-A1 | KAT6 INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2025-01-09 | — | — | WO | disclosed |
| WO-2024115733-A1 | FUSED PYRROLYL-SULFONAMIDE COMPOUNDS | REWIND THERAPEUTICS NV (BE) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024026433-A2 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-3747862-A1 | ALDH2 ACTIVATOR | Eisai R&D Management Co., Ltd. (JP) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747862-A1 | ALDH2 ACTIVATOR | Eisai R&D Management Co., Ltd. (JP) | 2020-12-09 | — | — | EP | disclosed |
| CN-1861077-A | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO INC (US) | 2006-11-15 | — | — | CN | disclosed |
| US-7125873-B2 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1412357-B1 | BETA-AMINO TETRAHYDROIMIDAZO(1,2-A)PYRAZINES AND TETRAHYDROTRIAZOLO(4,3-A)PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO INC (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1625847-A1 | Pharmaceutical composition comprising a tetrahydrotriazolo[4,3-a]pyrazine | Merck & Co., Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20040167133-A1 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2004-08-26 | — | — | US | disclosed |
| CN-1524082-A | Beta-aminotetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotriazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | — | 2004-08-25 | — | — | CN | disclosed |
| EP-1412357-A1 | BETA-AMINO TETRAHYDROIMIDAZO(1,2-A)PYRAZINES AND TETRAHYDROTRIAZOLO(4,3-A)PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6699871-B2 | SUCH AS 7-((3R)-3-AMINO-4-(3,4-DIFLUOROPHENYL)BUTANOYL)-2-(TRIFLUOROMETHYL)-5,6,7,8 -TETRAHYDROIMIDAZO(1,2-A)PYRAZINE DIHYDROCHLORIDE FOR TREATMENT OF INSULIN RESISTANCE DISORDERS | MERCK & CO., INC. | 2004-03-02 | — | — | US | disclosed |
| US-20030100563-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | SALZUFER HOLDING INC., AS ADMINISTRATIVE AGENT | 2003-05-29 | — | — | US | disclosed |
| WO-2003004498-A1 | BETA-AMINO TETRAHYDROIMIDAZO (1, 2-A) PYRAZINES AND TETRAHYDROTRIOAZOLO (4, 3-A) PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167133-A1 | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | KDM1A 2107/4885KDM1B 2187/4885KCNH2 2301/4885 |
| US-20030100563-A1 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | KDM1A 2806/4885KDM1B 2091/4885KCNH2 2900/4885 |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP3, DPP7 | KDM1A 672/4885KDM1B 917/4885KCNH2 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.